Related Experiment Videos
Pneumocystis carinii pneumonia: a lethal complication of "pulse" methylprednisolone therapy
G A Kozeny1, J P Quinn, V K Bansal
1Section of Nephrology, Loyola University Medical Center, Maywood, Illinois.
The International Journal of Artificial Organs
|September 1, 1987
Abstract:
A previously healthy, HIV-negative, 67-year-old man developed rapidly progressive glomerulonephritis. Following "pulse" methylprednisolone therapy he developed Pneumocystis carinii pneumonia. This complication should be recognized as a potential hazard of "pulse" steroid therapy.
Insights
High-dose steroid therapy can lead to Pneumocystis pneumonia in patients with rapidly progressive glomerulonephritis. This serious complication highlights the risks associated with pulse steroid treatments.
Area of Science:
- Nephrology
- Infectious Diseases
- Immunology
Background:
- Rapidly progressive glomerulonephritis (RPGN) is a severe kidney disease.
- Immunosuppressive therapy is often required for RPGN management.
- Pulse methylprednisolone is a common high-dose steroid regimen.
Observation:
- A 67-year-old, previously healthy, HIV-negative male presented with RPGN.
- The patient received intravenous pulse methylprednisolone therapy.
- Post-treatment, the patient developed Pneumocystis carinii pneumonia (PCP).
Findings:
- Pneumocystis carinii pneumonia (PCP) occurred as a complication of pulse steroid therapy.
- This suggests a link between high-dose corticosteroids and opportunistic infections like PCP.
- The patient's underlying condition was RPGN, not HIV, indicating broader risk factors.
Implications:
- Physicians should be aware of the risk of PCP with pulse steroid therapy, even in non-HIV patients.
- Prophylactic measures against Pneumocystis pneumonia may be considered during high-dose immunosuppression.
- This case underscores the need for careful monitoring and risk assessment in patients undergoing intensive immunosuppressive treatments.